NCT03099603View on ClinicalTrials.gov

A Study of HTD1801 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 24, 2017

Primary Completion Date

July 11, 2017

Study Completion Date

October 3, 2017

Conditions
Primary Sclerosing Cholangitis
Interventions
DRUG

HTD1801

A small molecular compound for the treatment of primary sclerosing cholangitis

Trial Locations (1)

3004

Nucleus Network Limited, Melbourne

All Listed Sponsors
lead

HighTide Biopharma Pty Ltd

INDUSTRY

NCT03099603 - A Study of HTD1801 in Healthy Subjects | Biotech Hunter | Biotech Hunter